A whole new way to reduce clinical mastitis and help protect her potential is here.
Imrestor (pegbovigrastim injection) helps restore the integrity of a cow’s innate immune system during the time when she experiences periparturient immune suppression.
Available only by veterinary prescription, Imrestor is FDA-approved for the reduction in the incidence of clinical mastitis in the first 30 days of lactation in periparturient dairy cows and periparturient replacement dairy heifers.
Even the best producers need a little help protecting their dairy herds
- HELP RESTORE - the function and increase the number of neutrophils when periparturient immune suppression leaves her vulnerable to infection
- REDUCE - the incidence of clinical mastitis around calving by 28%
- HELP PROTECT - her potential and the well-being of the entire dairy, as well as minimize the frustration of treating mastitis, with a product that is proven safe and effective for your herd
Imrestor is just the helping hand a dairy needs.
Important Safety Information
- See label for complete use information.
- Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
- Not for use in humans. Keep out of reach of children. In case of accidental self-injection, wash the site of injection thoroughly with clean running water. Foreign proteins such as pegbovigrastim have the potential to cause anaphylactic-type reactions.
- No withdrawal period or milk discard time is required when used according to the labeling.
- Do not use Imrestor to treat cows with clinical mastitis because effectiveness has not been demonstrated for this use.
- Some cases of hypersensitivity-type reactions have been observed in studies outside the United States within five minutes to two hours, occurring most often after the first administration of Imrestor. Clinical signs may include elevated respiratory rate, dyspnea, urticaria, sweating, dependent edema, swollen mucous membranes, and/or hypersalivation, and, rarely, death. These reactions resolve within hours of onset with or without therapeutic intervention and have not been shown to reoccur with subsequent injections of Imrestor.
- Abomasal ulcerations/erosions were observed in the Margin of Safety studies; it was concluded that these findings were not clinically relevant.